Norges Bank’s Humacyte HUMA Stock Holding History

Norges Bank’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-374,176	Closed	-$1.07M	–	2001
2023 Q2	$1.07M	Buy	+374,176	New	+$1.35M	﹤0.01%	1926

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Norges Bank's HUMA Position: Q3 2023 in Review

Norges Bank sold out of Humacyte (HUMA) in Q3 2023, closing a stake of 374,176 shares — an estimated $1.07M sold.

Norges Bank first reported a position in HUMA in Q2 2023 and held it in 1 quarter. The position peaked at $1.07M in Q2 2023. 83 funds tracked by Wall St. Rank hold HUMA as of Q3 2023.

Norges Bank reported no remaining Humacyte position as of Q3 2023 after selling out during the quarter.
Norges Bank sold 374,176 Humacyte shares in Q3 2023, an estimated $1.07M.
Norges Bank first reported a position in Humacyte in Q2 2023 and held it in 1 quarter.
Norges Bank's Humacyte position peaked at $1.07M in Q2 2023.
83 funds tracked by Wall St. Rank held Humacyte as of Q3 2023.

Based on Norges Bank's 13F filing for Q3 2023, filed 13 Nov 2023.